49 results on '"SONG Yan"'
Search Results
2. C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse
3. Economic Burden and Treatment Patterns Among Patients with Mantle Cell Lymphoma in the US: A Retrospective Claims Analysis
4. Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of US Claims Data
5. Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel or Other Donor Sources in Patients with Hematologic Malignancies: Comparison of Clinical Trial Results to Center for International Blood and Marrow Transplant Research Database Controls
6. Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy
7. Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma
8. Maintenance Therapy in Patients with FLT3-ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival
9. Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13
10. A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action
11. A Phase 1 Dose-Escalation Study of LH031, a Kinesin Spindle Protein Inhibitor, in Patients with Refractory/Resistance Multiple Myeloma
12. Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity
13. Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
14. Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity
15. Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13
16. Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma
17. Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells
18. Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma
19. Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
20. Identification of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma
21. Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells
22. Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma
23. Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3-Mutated (FLT3mut) and FLT3-Wild Type (FLT3wt) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study
24. Sumoylation of Pyruvate Kinase M2 Inhibits Myeloid Differentiation in Hematopoietic Cells
25. Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers
26. SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma
27. Combination of a Novel HDAC 6 Inhibitor ACY-241 with Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
28. Deubiquitylating Enzyme USP1 As Therapeutic Target in Multiple Myeloma
29. Deubiquitylating Enzyme Rpn11/POH1/PSMD14 As Therapeutic Target in Multiple Myeloma
30. Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo
31. The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells
32. Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma
33. A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism
34. Targeting 19S-Proteasome Deubiquitinase Rpn11/POH1/PSMD14 in Multiple Myeloma
35. Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
36. Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study
37. Identification of Metabolic Enzymes ENO1 and KMO As Novel Immunotherapeutic Targets in Myeloma
38. Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects
39. Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839
40. SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis
41. Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma
42. A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells
43. Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001
44. Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide
45. Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia
46. Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance ViaTargeting Ubiquitin Receptor Rpn13
47. Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma
48. Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitroand In Vivo
49. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.